News

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

The benchmark US stock measures were pointing higher before the opening bell Monday as President Don

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir

BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.

Moby summary of Bristol-Myers Squibb Company's Q2 2026 earnings call

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively tra

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

Bristol-Myers Squibb Company will release earnings for its second quarter before the opening bell on Thursday, July 30. Analysts expect the company to report quarterly earnings of $1.60 per share, up from $1.46 per share in the year-ago period. The...

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for.

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q